Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Critical roles of TRAIL in hepatic cell death and hepatic inflammation
Shi-Jun Zheng, … , Galit Tsabary, Youhai H. Chen
Shi-Jun Zheng, … , Galit Tsabary, Youhai H. Chen
Published January 1, 2004
Citation Information: J Clin Invest. 2004;113(1):58-64. https://doi.org/10.1172/JCI19255.
View: Text | PDF
Article Immunology

Critical roles of TRAIL in hepatic cell death and hepatic inflammation

  • Text
  • PDF
Abstract

The TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis of tumor cells but not most normal cells. Its role in hepatic cell death and hepatic diseases is not clear. In vitro studies suggest that murine hepatocytes are not sensitive to TRAIL-induced apoptosis, indicating that TRAIL may not mediate hepatic cell death. Using two experimental models of hepatitis, we found that hepatic cell death in vivo was dramatically reduced in TRAIL-deficient mice and mice treated with a blocking TRAIL receptor. Although both TRAIL and its death receptor 5 were constitutively expressed in the liver, TRAIL expression by immune cells alone was sufficient to restore the sensitivity of TRAIL-deficient mice to hepatitis. Thus, TRAIL plays a crucial role in hepatic cell death and hepatic inflammation.

Authors

Shi-Jun Zheng, Pu Wang, Galit Tsabary, Youhai H. Chen

×

Figure 5

Options: View larger image (or click on image) Download as PowerPoint
TRAIL expression by cells of the immune system is required for the devel...
TRAIL expression by cells of the immune system is required for the development of Con-A–induced hepatitis. TRAIL+/+ or TRAIL–/– liver MNCs (2 × 107 cells per mouse) and splenocytes (3 × 107 cells per mouse) were transferred into TRAIL–/– mice intrahepatically and intrasplenically, respectively. One hour later, mice were injected with Con-A (25 mg/kg of body weight), and serum activities of ALT were assessed 12 hours after the challenge. Data presented are means and SEM of each group (n = 5). Results shown are from one representative experiment of two. The differences between the two groups are statistically significant as determined by ANOVA (P < 0.01).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts